Annual report pursuant to Section 13 and 15(d)

Accrued Expenses and Other Liabilities

v3.21.1
Accrued Expenses and Other Liabilities
 12 Months Ended
Dec. 31, 2020
Payables and Accruals [Abstract]  
Accrued Expenses and Other Liabilities

Note 7 – Accrued Expenses and Other Liabilities

 

Accrued expenses and other liabilities, summarized by major category, consist of the following for years ended December 31, 2020 and 2019 (in thousands):

 

    2020     2019  
    As of December 31,  
    2020     2019  
Payroll and incentives   $ 1,094     $ 978  
General and administrative expenses     280       441  
Research and development expenses     778       421  
Deferred revenue and other deferred liabilities * 643       100  
Total   $ 2,795     $ 1,940  

 

* At December 31, 2020, approximately $576.6 thousand is the remaining balance of the CFF Agreement’s deferred liability and approximately $66.6 thousand is deferred revenue related to the Genentech feasibility study agreement. The $100.0 thousand of deferred revenue at December 31, 2019 is the upfront payment for the Genentech feasibility study agreement.